Search
Peptide Therapeutics has recently announced the successful closure of its Series B funding round, raising nearly RMB 100 million. This round was led by Dinghui Investment. As a biomedical enterprise, Peptide Therapeutics specializes in the research and development of peptide-based lead drugs. The company has established a colossal peptide entity library comprising approximately 500 million peptide sequences and six complementary molecular discovery libraries, bolstered by 110 invention patents. Notably, the Peptide Information Compression Technology (PICT) patent has been granted in multiple countries. The proceeds from this funding round will be allocated towards advancing self-developed pipeline projects, enhancing the AI drug development platform, and other strategic initiatives.
-
C114 Communication Network -
Communication Home
